Amyotrophic Lateral Sclerosis (ALS)
Patient Condition
The patient developed weakness in his right hand at the age of 50, which gradually progressed to the limbs and trunk. Amyotrophic lateral sclerosis (ALS) was diagnosed 6 months before his visit. The ALSFRS-R score was 32 points, with a decrease rate of 1.2 points per month. Upper limb muscle strength level 3, lower limb muscle strength level 4. Respiratory function: FVC 78% predicted, maximum inspiratory pressure (MIP) 60 cmH2O. Neurofilament light chain (NfL) increased to 68 pg/mL. Having been using riluzole for 6 months, the results are not good.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| AMX0035 Combination Therapy Launched | ||
| Stem cell-adjuvant therapy | ||
| Long-term maintenance follow-up |
Treatment Outcome
| before | ALSFRS-R 32 points, decline rate 1.2 minutes/month, upper limb muscle strength grade 3, FVC 78%, NfL 68 pg/mL, 6 months of riluzole treatment failed |
|---|---|
| after | ALSFRS-R 30 points, the rate of decline dropped to 0.08 minutes/month, upper limb muscle strength level 4, FVC 68%(stable for 24 months), NfL dropped to 38 pg/mL, no non-invasive ventilation support was required, and the condition was stable for 24 months |
| highlight | Disease progression rate is reduced by 93%, lung function is maintained for a long time, and combination therapy + stem cells help achieve long-term stabilization of ALS and return to normal work and family life. |